Generation Bio is a biotechnology company changing what is possible for people living with T cell-driven autoimmune diseases. The company is developing novel therapeutics leveraging its T cell selective cell-targeted lipid nanoparticle (ctLNP) to deliver siRNA in vivo, enabling modulation of T cell activity that causes inflammation and auto-reactive tissue destruction. By selectively modulating T cells that drive disease pathology, ctLNP-siRNA therapeutics could potently block target function with sequence-level specificity while sparing the broader immune system. This potent new modality is designed to reach targets that are poorly drugged by other approaches, opening a broad indication space of T cell driven autoimmune diseases.
We are a thriving, collaborative, creative community of 100 people with diverse talents, beliefs, and experiences headquartered in Cambridge, Massachusetts.
Delve further. Please visit www.generationbio.com or follow @generationbio. To see additional roles, please also check out https://generationbio.com/careers/
SUMMARY:
Generation Bio is seeking an energetic and motivated Associate Director/ Director with experience and technical expertise building siRNA-based therapies. The successful candidate will oversee strategy for optimizing siRNA cargo and be responsible for integration of workflows to identify lead siRNA molecules in support of therapeutic programs. As part of this effort, the Associate Director/ Director will establish the core infrastructure required for iterative design and evaluation of siRNA molecules to drive program and platform development. The position is cross-functional, requiring collaboration with delivery and preclinical teams to develop siRNA cargo that satisfies program needs. The Associate Director/ Director will be responsible for building an infrastructure with the technical capabilities to address platform development goals. This position reports to the VP, Head of Molecular Biology.
RESPONSIBILITIES:
- Lead design approaches for optimizing siRNA therapeutic molecules for high potency, selectivity and durability
- Establish the core infrastructure required for iterative design and evaluation of siRNA molecules to drive program and platform development – including target evaluation, candidate screening, optimization of chemical modifications and off target analysis/ mitigation.
- Play a key role in developing criteria for deciding which targets and associated programs to advance and why.
- Oversee strategy for platform assay development and implementation
- Collaborate with pre-clinical teams to develop therapeutic molecules based on program needs.
- Present scientific ideas and results effectively to R&D teams and senior management.
- Accountable for on-time execution of experimental projects to advance our platform.
QUALIFICATIONS:
- PhD in Molecular Biology, Cell Biology, Synthetic biology, Bioengineering, Biochemistry or related discipline.
- Relevant industry experience advancing complex programs from ideation to IND enabling studies.
- Specific experience with platform development of oligonucleotide cargo
- Deep understanding of molecular/ chemical attributes of oligonucleotide molecules and their translation to function in therapeutic context is desirable
- Experience with driving the process of identifying lead molecules to support therapeutic programs is highly desired.
- Experience managing direct reports and working cross functionally is essential
- Capacity for innovative thinking and critical problem solving.
- Strong desire to develop groundbreaking genetic medicines
- Excellent communication and interpersonal skills with capacity and proven track record of working cross functionally.
POSITION: Full-Time, Exempt
EEOC Statement: Generation Bio believes in a diverse environment and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race (to include traits historically associated with race including, but not limited to, hair texture, hair type, hair length, and protective hairstyles such as braids, locks, twists, hair coverings, and Bantu knots), color, gender, religion, national origin, gender identity, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Generation Bio will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Top Skills
What We Do
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support their mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
